Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genticel
Labège/Toulouse, Occitanie, Francegenticel.com ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Other
01
Overview
Genticel developed therapeutic vaccines targeting women already infected with high-risk human papillomavirus types to prevent progression to cervical cancer. Its lead candidate, GTL001/ProCervix, reached Phase II clinical trials but failed to meet its primary endpoint mid-trial; however, subsequent results were more promising. A second-generation multivalent vaccine candidate, GTL002, achieved preclinical proof-of-concept.
- Therapeutic areas
- Women's Health
- Modalities
- VaccineProteinBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Genticel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genticel.